ReGEN Podcast Podcast Por Bobby Gordon arte de portada

ReGEN Podcast

ReGEN Podcast

De: Bobby Gordon
Escúchala gratis

The Sanford Stem Cell Institute (SSCI) ReGen Podcast features engaging and innovative discussions with a focus on the following topics: stem cell science; regenerative medicine; clinical trials; research outcomes; and, space and low Earth orbit-based research. Guests include UC San Diego Sanford SSCI experts and team members, academic luminaries, Nobel laureates, and industry and government leaders in the field. The ReGen Podcast is based in San Diego, CA, and is hosted by SSCI team member Bobby Gordon. About the Sanford Stem Cell Institute The UC San Diego Sanford Stem Cell Institute (SSCI) is a global leader in regenerative medicine and a hub for stem cell science and innovation in space, representing six (6) research Centers, the CIRM Alpha Stem Cell Clinic, and a Brain Tumor & Neuro-Restoration Program. SSCI aims to catalyze critical basic research discoveries, translational advances, and clinical progress — terrestrially and in space — to develop and deliver novel therapeutics to patients.©2025 UC San Diego All Rights Reserved Ciencia Enfermedades Físicas Higiene y Vida Saludable
Episodios
  • Holly Young, MSc, Cell Therapy Production at UC San Diego

    Holly Young, MSc, Cell Therapy Production at UC San Diego
    Aug 8 2025
    This episode features Holly Young, MSc, who serves as the facility director of the Advanced Cell Therapy Laboratory (ACTL), as part of the Sanford Advanced Therapy Center at UC San Diego. The mission of ACTL is to provide leading-edge services for the development and production of innovative cell therapy products, to support UC San Diego and other researchers in the transition from research and development to clinically relevant manufacturing of cell therapy products; to improve patient treatments. Learn more at actl.ucsd.edu. Hosted by Bobby Gordon. This episode was recorded on January 30, 2025 and information presented is current as of this date.
    Más Menos
    22 m
  • Dr Kenneth Savin, Redwire | Groundbreaking ISS Biotech Discoveries

    Dr Kenneth Savin, Redwire | Groundbreaking ISS Biotech Discoveries
    Aug 4 2025
    This episode features our conversation with Dr Kenneth A. Savin, Chief Scientist at Redwire. Dr. Savin was named to TIME’s “2025 TIME100 Health List of the 100 Most Influential People in Global Health.” We discuss his 20-plus year career and expertise in the pharmaceutical industry and his pioneering work accelerating cutting-edge space biotech research capabilities, leveraging microgravity to improve human health on Earth. At Redwire, Dr. Savin has overseen trailblazing investigations onboard the International Space Station (ISS) in partnership with NASA and the ISS National Laboratory. Redwire successfully bioprinted the first human knee meniscus and first live human cardiac tissue using its BioFabrication Facility on the ISS. These breakthroughs address challenges faced by millions of people worldwide through the application of organ transplantation and tissue therapy and advance the next generation of pharmaceutical therapies. Dr. Savin has coordinated groundbreaking protein crystallization investigations onboard the ISS with pharmaceutical companies like Eli Lilly and Company (Lilly) and Bristol Myers Squibb using Redwire’s in-space pharmaceutical lab, PIL-BOX, for improved drug development. These investigations have focused on various applications to address the world’s most prevalent conditions, including antiviral, antifungal, and antiseizure applications, heart disease, and bone loss. Hosted by Bobby Gordon. This episode was recorded on December 2, 2024, and information presented in this episode is current as of this date.
    Más Menos
    32 m
  • Dr. Catriona Jamieson | The Search for Cancer Cures in Outer Space

    Dr. Catriona Jamieson | The Search for Cancer Cures in Outer Space
    Jun 25 2025
    This episode’s conversation focuses on the innovative work of Dr. Catriona Jamieson, Director of the Sanford Stem Cell Institute at UC San Diego, and the Axiom-4 (Ax-4) launch. This space research mission includes the Institute’s testing of the efficacy of “rebecsnib” on tumor organoids derived from cancer stem cells of consenting patients with secondary acute myeloid leukemia, ovarian cancer, metastatic breast cancer and glioblastoma multiforme. The drug holds potential to fight 23 types of cancer — any that involve ADAR1 in their development and progression. The hope is that the investigational new drug prevents the miniature tumors from growing, as it did on Axiom Space’s previous Ax-3 mission, with cell line-derived triple negative breast cancer tumor organoids. Hosted by Bobby Gordon This episode was recorded on June 6, 2025, and information presented is accurate as of this date.
    Más Menos
    29 m
Todavía no hay opiniones